drugset / Trial / NCT01423305

Phase I Pharmacokinetic Study (BF-BLOCK)

NCT01423305

Phase 1 Completed 20 enrolled Orion Corporation, Orion Pharma
RandomizedCrossoverOpen-labelTreatment

Summary

The objective of the study is to assess if charcoal prevents the absorption of budesonide and formoterol via GI track. The assessment will be based on comparing the pharmacokinetic parameter area under the concentration-time curve.

Timeline

Start
2011-08
Primary completion
2011-10
Completion
2011-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Budesonide Small molecule Oral
Subject Formoterol Other / unclassified Oral

Indications